Elliot Tapper(@ebtapper) 's Twitter Profile Photo

MAESTRO-NASH is a positive trial

Resmetirom improved NASH resolution and reduced fibrosis at 52-weeks. It is safe.

Is it a landmark study? Yes
Will it change NASH? Depends on cost, adherence in real world, and effect on clinical outcomes

MAESTRO-NASH is a positive trial

Resmetirom improved NASH resolution and reduced fibrosis at 52-weeks. It is safe.

Is it a landmark study? Yes
Will it change NASH? Depends on cost, adherence in real world, and effect on clinical outcomes #EASLCongress #LiverTwitter
account_circle
Carlotta Mayer(@c_ma_yer) 's Twitter Profile Photo

You want to learn about the latest structure in the liver, the apical bulkheads, and their role in liver disease? Come to poster 390 today 👍
EASLnews EASL Education

You want to learn about the latest structure in the liver, the apical bulkheads, and their role in liver disease? Come to poster 390 today 👍
#EASLCongress @EASLnews @EASLedu #LiverTwitter
account_circle
Juan Turnes(@jturnesv) 's Twitter Profile Photo

Final results of phase 3 RCT in with Liver fibrosis F1-F3:

⬇️ 30% Liver fibrosis
⁉️ Very low rate of placebo response
✅ Good safety profile
⏰ Clinical outcomes still under assessment

Is this enough?

Ian Rowe

Final results of #Resmetirom phase 3 RCT in #NASH with Liver fibrosis F1-F3:

⬇️ 30% Liver fibrosis
⁉️ Very low rate of placebo response 
✅ Good safety profile 
⏰ Clinical outcomes still under assessment 

Is this enough?

#EASLCongress #livertwitter @IanARowe
account_circle